Stay updated
Successful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007
MapLight Therapeutics Announces Successful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007 Study assessed safety, tolerability, and pharmacokinetics (PK)
MapLight Therapeutics Appoints Tim Garnett, M.D. to Board of Directors
MapLight Therapeutics Appoints Tim Garnett, M.D. to Board of Directors Industry Leader Appointed to MapLight’s Board of Directors SAN FRANCISCO, July 24, 2023 –
MapLight Therapeutics Appoints Kris Hanson as General Counsel
MapLight Therapeutics Appoints Kris Hanson as General Counsel Hanson Brings 25 Years of Experience Advising Public and Private Companies to MapLight as the New Legal
MapLight Therapeutics Appoints Dr. Matthew State And Dr. Ivan Soltesz to Scientific Advisory Board
MapLight Therapeutics Appoints Dr. Matthew State and Dr. Ivan Soltesz to Scientific Advisory Board MapLight’s drug discovery expertise is further strengthened by the addition of
MapLight Therapeutics Appoints Hongkui Zeng, Ph.D. to Scientific Advisory Board
Dr. Zeng Brings Deep Expertise in Single-Cell Transcriptomics and Brian Circuit Connectivity to MapLight’s Scientific Advisory Board
MapLight Therapeutics Announces Completion Of Phase 1 Clinical Trial For ML-007, A Novel Therapy For The Treatment Of Schizophrenia And Dyskinesias
18.08.2022 MapLight Therapeutics Announces Completion Of Phase 1 Clinical Trial For ML-007, A Novel Therapy For The Treatment Of Schizophrenia And Dyskinesias First in human
MapLight announces initiation of Phase 1 Clinical Trial to treat patients with Schizophrenia or Dyskinesias
Initial study is enrolling healthy patients across seven cohorts to assess safety, tolerability, and pharmacokinetic profile related to ML-007 therapy.
MapLight receives additional funding from the Michael J. Fox Foundation for Parkinson’s Research
The $1.75M award builds on a $5.5M grant from MJFF announced earlier this month. MapLight also received an $8.1M award from MJFF in 2020.
MapLight awarded $5.5M from Michael J. Fox Foundation for Parkinson’s Research
MapLight’s promising platform continues to garner support from leading Parkinson’s research foundation.
MapLight Therapeutics appoints Erin Pennock Foff, M.D., Ph.D., as Chief Medical Officer
Dr. Foff Joins MapLight to Help Further Advance the Company’s Portfolio of Novel Therapeutics for Patients with Disorders of the Central Nervous System (CNS).
MapLight Therapeutics receives $8.1 million for Parkinson’s Disease research
Results will inform identification of novel drug targets and therapeutic strategies to address anxiety and depression related to Parkinson’s disease neurodegeneration.
MapLight Therapeutics announces completion of dosing in Phase 1 Study of therapy for Social Deficit in Autism Spectrum Disorder
Interim data from Phase 1 clinical trial with repeated dosing in healthy volunteers demonstrates positive safety and tolerability profile for ML-004.
Michael J. Fox Foundation Announces Grant Funding to MapLight Therapeutics
This new grant totaling more than $16.5 million will serve our mission to find a cure for Parkinson’s and improved treatments for those living with the disease today.
